ROLE OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTORS IN THE TREATMENT OF CHRONIC AND RECURRENT CENTRAL SEROUS CHORIORETINOPATHY

Authors

  • MADAKI S.M Department of Ophthalmology,Gombe State University, Gombe State, Nigeria.
  • SONJOY D.K Vitreoretina Department, Ispahani Islamia Eye Institute and Hospital, Dhaka (IIEIH), Bangladesh
  • HABIB S.G Department of ophthalmology, Aminu Kano Teaching Hospital/ Bayero University Kano, Kano State

Keywords:

Chronic central serous chorioretinopathy, neurosensory retinal detachment, Subretinal fluid, Anti-vascular endothelial growth factor, Optical Coherence Tomography.

Abstract

The study evaluate the role of anti-vascular endothelial growth factors (Anti-Vegf) in the treatment
of chronic central serous chorioretinopathy (CSCR). It was a hospital base prospective
interventional non randomized study. Patients with history of chronic CSCR lasting for more than
3 months were treated with intravitreal Bevacizumab 1.25mg or Ranibizumab 0.5mg after
measurement of best corrected visual acuity (BCVA), intraocular pressure (IOP), dilated fundus
examination and central macular thickness using OCT. Patient shows complete resolution of
subretinal fluid and restoration of visual acuity to normal after 3months. In conclusion, intravitreal
injection of anti-vegf results in restoration of normal vision in patient with CSCR.

Downloads

Published

2021-06-13

How to Cite

S.M, M. ., D.K, S., & HABIB S.G. (2021). ROLE OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTORS IN THE TREATMENT OF CHRONIC AND RECURRENT CENTRAL SEROUS CHORIORETINOPATHY. BIMA JOURNAL OF SCIENCE AND TECHNOLOGY (2536-6041), 5(01), 275-281. Retrieved from https://journals.gjbeacademia.com/index.php/bimajst/article/view/284

Issue

Vol. 5 No. 01 (2021): Vol. 5 No. 1 June 2021

Section

Articles